$吉利德科学(GILD)$@正义创造力量: GILD: Vaccines Will Underwhelm, And Why Gilead Has A Substantially Larger Market Opportunity7:04 am, Sat, Jun. 20, 2020, by Et al BioCapitalSummaryThe complex immunogenicity of ** strongly suggests vaccines and antibody treatments are unlikely to deliver meaningful results.We are unlikely to develop immunity to **, making it our newest endemic virus.Antivirals are the best and most practical way to treat **.Antivirals such as Gilead’s Remdesivir have a significantly bigger clinical need and market opportunity than is currently appreciated.We estimate Gilead has a multi-year, multi-billion dollar opportunity with Remdesivir.